γ-AApeptides Inhibit Neurodegenerative Protein Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases such as Alzheimer's and Huntington's are inadequate, as they fail to effectively inhibit or disrupt the aggregation of proteins like tau, synuclein, and amyloid-beta, which are central to disease progression.
Innovation Solution
The development of γ-AApeptides, specifically HW-C-9, which can inhibit or disrupt the aggregation of tau, synuclein, and amyloid-beta peptides, offering a potential treatment by administering these compounds or their pharmaceutically acceptable salts to reduce protein aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for neurodegenerative diseases, then treatment is provided, but they fail to effectively inhibit or disrupt protein aggregation
Solution Approach 1:
The patent introduces γ-AApeptides as intermediary molecules that mediate between the therapeutic goal and the pathogenic proteins. These peptides act as mediators that specifically bind to and disrupt the aggregation of tau, synuclein, and amyloid-beta through their unique γ-amino acid backbone structure, which provides novel binding interfaces not present in conventional α-peptide-based therapies
Solution Approach 2:
The invention changes the fundamental chemical parameter of the peptide backbone from the conventional α-configuratioγn to the γ-configuratioγn, which alters the spatial arrangement and chemical properties of the peptide. This parameter change enables the peptides to effectively inhibit protein aggregation while maintaining stability and reducing toxicity, thereby resolving the contradiction between providing effective treatment and avoiding harmful aggregation
2Reliability
If new compounds like γ-AApeptides are developed, then protein aggregation inhibition is improved, but the complexity of the treatment increases
Solution Approach 1:
The patent segments the complex problem of neurodegenerative disease treatment into targeted components by designing specific γ-AApeptides for different pathogenic proteins (tau, synuclein, amyloid-beta). Each peptide variant is optimized for its specific target, allowing for modular development and testing. This segmentation approach manages complexity by breaking down the overall therapeutic challenge into discrete, manageable peptide designs with specific functions
Solution Approach 2:
The γ-AApeptide platform provides a universal solution that can address multiple different neurodegenerative diseases through a single core technology. The same γ-amino acid backbone structure and general mechanism of action can be applied to inhibit aggregation of various different proteins by simply modifying the specific peptide sequence, thereby reducing overall treatment complexity through a multi-functional platform approach
Data Source
AI summary
Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.